ArticleVirulence2021
Oral administration of
Article in Virulence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Microbiota-Immune Crosstalk in Pneumonia and Acute Lung Injury: Mechanisms, Evidence, and Therapeutic Opportunities.Microorganisms · 2026Review
- Article
- The role ofFrontiers in immunology · 2026Review
- Fuzheng Jiedu Formula Ameliorates Acute Lung Injury by Modulating Gut Microbiota to Enhance Short-Chain Fatty Acid.Journal of inflammation research · 2026Article
- The impact of metabolic reprogramming on tertiary lymphoid structure formation: enhancing cancer immunotherapy.BMC medicine · 2025Review
- Microbiome modifications by steroids during viral exacerbation of asthma and in healthy mice.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Review
- Host tracheal and intestinal microbiomes inhibitMicrobiology spectrum · 2024Article
- Gut-Derived Short-Chain Fatty Acids and Macrophage Modulation: Exploring Therapeutic Potentials in Pulmonary Fungal Infections.Clinical reviews in allergy & immunology · 2024Review
- Review
- A new perspective on gut-lung axis affected through resident microbiome and their implications on immune response in respiratory diseases.Archives of microbiology · 2024Review
- Effects of antibiotic therapy on the early development of gut microbiota and butyrate-producers in early infants.Frontiers in microbiology · 2024Article
- Host tracheal and intestinal microbiomes inhibitbioRxiv : the preprint server for biology · 2023Article
- Coccidioidomycosis and Host Microbiome Interactions: What We Know and What We Can Infer from Other Respiratory Infections.Journal of fungi (Basel, Switzerland) · 2023Review
- Alveolar macrophage modulation via the gut-lung axis in lung diseases.Frontiers in immunology · 2023Review
- Altered intestinal microbiota in children with bronchiolitis.Frontiers in microbiology · 2023Article
- Impact of Lung Microbiota on COPD.Biomedicines · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Changes in the intestinal microbiota indirectly impact the health of mucosa distal to the intestine, particularly the respiratory tract. However, the effects of intestinal microbiota dysbiosis on the regulation of respiratory syncytial virus (RSV) infection are not clear. In this study, we examined the effects of altering the intestinal microbiota on the pulmonary immune response against RSV infection. BALB/c mice were treated with streptomycin before infection with RSV to study the altered immune response. The ingestion of streptomycin led to a marked alteration in the intestinal microbiota with a reduced abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.